Methods and compositions involving LcrV proteins

Details Methods and compositions involving LcrV proteins Methods and compositions involving LcrV proteins

2011-01-25

2011-01-25

Minnifield, N M (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C536S023700

Reexamination Certificate

active

07875280

ABSTRACT:
The present invention concerns methods and compositions involving modified LcrV proteins fromYersiniabacteria. These methods and compositions can be employed to invoke an immune response in a subject against the bacteria, while not suppressing the immune system as much as the native LcrV protein. In certain embodiments, the present invention relates to vaccines, as well as methods to protect a subject againstYersinia pestisand plague. Moreover, the present invention concerns methods and compositions for suppressing a subject's immune system using non-native LcrV polypeptides.

REFERENCES:
patent: 5985285 (1999-11-01), Titball et al.
patent: 6638510 (2003-10-01), Brubaker et al.
patent: 6964770 (2005-11-01), Brubaker et al.
patent: 2005/0232940 (2005-10-01), Brubaker et al.
Sarker et al. (J. Bacteriol., 180:1207-1214, 1998.
Harlow et al. (Antibodies, a Laboratory Manual, Cold Spring Harbor Laboratory, 1988, p. 67).
Bello et al. (Plastic and Reconstructive Surgery, 119:1326-1336, 2007).
Anderson et al., “Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains ofYersinia pestis,” Infect. Immun., 64:4580-4585, 1996.
Anisimov et al, “Intraspecific diversity ofYersinia pestis,” Clin. Microbial. Rev., 17(2):434-464, 2004.
Bergman et al., “Analysis of the V antigen lerGVH-yopBD operon ofYersinia pseudotuberculosis: evidence for a regulatory role of LcrH and LcrV,”J. Bacteriol., 173:1607-1616, 1991.
Brubaker, “Interleukin-10 and inhibition of innate immunity toYersiniae: roles of Yops and LcrV (V antigen),”Infect. Immun., 71:3673-3681, 2003.
Brubaker, “Mutation rate to nonpigmentation inPasteurella pestis,” J. Bacteriol., 98:1404-1406, 1969.
Derewenda et al, “The structure ofYersinia pestisV-antigen, an essential virulence factor and mediator of immunity against plague,”Structure, 12:301-306, 2004.
Heath et al., “Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine,”Vaccine, 16:1131-1137, 1998.
Hill et al., “Regions ofYersinia pestisV antigen that contribute to protection against plague identified by passive and active immunization,”Infect. Immun., 65:4476-4482, 1997.
Jones et al., “Protection conferred by a fully recombinant sub-unit vaccine againstYersinia pestisin male and female mice of four inbred strains,”Vaccine, 19(2-3):358-366, 2000.
Kopp and Medzhitov, “A plague on host defense,”J. Exp. Med., 196:1009-1012, 2002.
Leary et al., “Active immunization with recombinant V antigen fromYersinia pestisprotects mice against plague,”Infect. Immun., 63:2854-2858, 1995.
Lee et al., “LcrV, a substrate forYersinia enterocoliticatype III secretion, is required for toxin targeting into the cytosol of HeLa cells,”J. Biol. Chem., 275:36869-36875, 2000.
Marketon et al., “Plague bacteria target immune cells during infection,”Science,309:1739-1741, 2005.
Motin et al., “Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide,”Infect. Immun., 62:4192-4201, 1994.
Motin et al., “V antigen-polyhistidine fusion peptide: binding to LcrH and active immunity against plague,”Infect. Immun., 64:4313-4318, 1996.
Nakajima and Brubaker, “Association between virulence ofYersinia pestisand suppression of gamma interferon and tumor necrosis factor alpha,”Infection and Immunity, 61:23-31, 1993.
Nakajima et al., “Suppression of cytokines in mice by protein A-V antigen fusion peptide and restoration of synthesis by active immunization,”Infect. Immun., 63:3021-3029, 1993.
Nedialkov et al., “Resistance to lipopolysaccharide mediated by theYersinia pestisV antigen-polyhistidine fusion peptide: amplification of interleukin-10,”Infection and Immunity, 65:1196-1203, 1997.
Niles, “Dissecting the structure of LcrV fromYersinia pestis, a truly unique virulence protein,”Structure, 12:357-358, 2004.
Overheim et al., “LcrV plague vaccine with altered immunomodulatory properties,”Infect. Immun., 73:5152-5159, 2005.
Perry and Fetherston, “Yersinia pestis—etiologic agent of plague,”Clin. Microbial. Rev., 10:35-66, 1997.
Pullen et al., “Analysis of theYersinia pestisV protein for the presence of linear antibody epitopes,”Infect. Immun., 66:521-527, 1998.
Russell et al., “A comparison of Plague vaccine, USP and EV76 vaccine induced protection againstYersinia pestisin a murine model,”Vaccine, 13:1551-1556, 1995.
Sawa et al., “Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury,”Nat. Med., 5:392-398, 1999.
Sing et al., “Contribution of toll-like receptors 2 and 4 in an oralYersinia enterocoliticamouse infection model,”Int. J. Med. Microbial., 293:341-348, 2003.
Sing et al., “Yersinia enterocoliticaevasion of the host innate immune response by V antigen-induced IL-10 production of macrophages is abrogated in IL-10-deficient mice,”J. Immunol., 168:1315-1321, 2002.
Sing et al., “YersiniaV-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression,”J. Exp. Med., 196:1017-1024, 2002.
Skrzypek and Straley, “Differential effects of deletions in lcrV on secretion of V antigen, regulation of the low-Ca2+ response, and virulence ofYersinia pestis,” J. Bacteriol., 177:2530-2542, 1995.
Studier et al., “Use of T7 RNA polymerase to direct expression of cloned genes,”Methods Enzymol., 185:60-89, 1990.
Titball and Williamson, “Yersinia pestis(plague) vaccines,”Expert Opin. Biol. Ther., 4:965-973, 2004.
Une and Brubaker, “Roles of V antigen in promoting virulence and immunity in yersiniae,”J. Immunol., 133:2226-2230, 1984.
Wang et al., “A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague,”Vaccine, 22:3348-3357, 2004.
Welkos et al., “Determination of the virulence of the pigmentation-deficient and pigmentation-/plasminogen activator-deficient strains ofYersinia pestisin non-human primate and mouse models of pneumonic plague,”Vaccine, 20:2206-2214, 2002.
Welkos et al., “Studies on the role of plasminogen activator in systemic infection by virulentYersinia pestisstrain C092,”Microb. Pathog., 23(4):211-223, 1997.

Affiliated with

Also associated with

Rating

Methods and compositions involving LcrV proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions involving LcrV proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions involving LcrV proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2646107